Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) FCF Margin (2019 - 2025)

Historic FCF Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 91.17%.

  • BridgeBio Pharma's FCF Margin rose 65231400.0% to 91.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 165.62%, marking a year-over-year increase of 417300.0%. This contributed to the annual value of 235.09% for FY2024, which is 54515300.0% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's FCF Margin is 91.17%, which was up 65231400.0% from 73.2% recorded in Q2 2025.
  • BridgeBio Pharma's FCF Margin's 5-year high stood at 16437.47% during Q4 2021, with a 5-year trough of 40213.61% in Q3 2022.
  • Over the past 5 years, BridgeBio Pharma's median FCF Margin value was 3560.43% (recorded in 2023), while the average stood at 5816.66%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's FCF Margin was 970989500bps (2021), while the steepest drop was -352619900bps (2021).
  • Over the past 5 years, BridgeBio Pharma's FCF Margin (Quarter) stood at 16437.47% in 2021, then plummeted by -131bps to 5029.09% in 2022, then plummeted by -43bps to 7177.88% in 2023, then surged by 54bps to 3321.54% in 2024, then surged by 97bps to 91.17% in 2025.
  • Its FCF Margin was 91.17% in Q3 2025, compared to 73.2% in Q2 2025 and 171.11% in Q1 2025.